CYAD JP Morgan Itinerary

Corporate Access Event
January 11 - 14, 2016

Meeting Schedule, January 11th – 14th

San Francisco, CA

French Biotech Co.

CEO, CFO
VP Business Development Strategic Advisor Immuno-Oncology

Company Meeting Location:

Sir Francis Drake Hotel
Room # 450 Powell
Street San Francisco, CA

If questions should arise, please contact:

Andrew McDonald

Mobile:

Email: [email protected]

Angela Qian

Mobile:

Email: [email protected]

-1

January 11 - 14, 2016

MEETINGS

Note: (*) indicates that this meeting time is double-booked.

Meeting Type

Time

Room

Meeting With

Note

Monday, January 11, 2016

08:00-09:00 am 09:00-10:00 am 10:00-11:00 am
Sir Francis Drake (450 1x1 Powell St), Room 530

Aquilo Capital

Patrick Rivers

Auriga Capital

Glen Losev
Hotel Nikko (222 Mason 1x1 St), 25th Floor, Bay View Room

Takeda

Kiran Philip
11:00-12:00 pm 12:00-1:00 pm

Granite Investment Partners

Jeffrey Hoo

LAST MINUTE CANCELLATION

Marriott Marquis (780 Mission St), Salon 14
1x1

AbbVie

Niels Emmerich
Onsite Contact: Tiffany Cincotta-Janzen, (847) 393-5723

01:30-02:00 pm

03:00-03:30 pm 04:00-05:00 pm

Alpine BioVentures, GP LLC

David Miller

Tara Capital Grp

Dhesh Govender

EVOLUTION Life Science Partners

Anton Gueth

Tuesday, January 12, 2016

07:00-08:30 am* 07:00-09:00 am*
Breakfast Breakfast
Fierce Biotech Big Data Breakfast BCG's Gene Editing Event
CEO will attend. will attend.

09:30-10:00 am 10:30-11:30 am* 11:00-11:30 am* 11:30-12:00 pm 12:00-12:45 pm*
Parc 55 San Francisco 1x1 (55 Cryil Magnin St)

Edison

Melissa Mayfield
Fairmont Hotel (950 Mason St)
1x1

Novartis

Silicon Valley Bank

Nooman Haque

Syncona Partners

Tim Funnell
Marriott Marquis (780 Mission St), Foothill G2 Room (Atrium Level)
1x1

Roche Partnering/Oncology

Scott Moorefield, Dr. Barbara Lueckel

12:00-01:00 pm*

Clift Hotel (495 Geary

1x1

Cowen and Company, LLC

-2

January 11 - 14, 2016

St)

Chris Swindle

01:00-01:45 pm

02:15-03:00 pm 03:00-04:00 pm* 03:15-06:30 pm* 04:00-05:00 pm* 04:30-05:00 pm* 05:00-06:00 pm* 05:30-06:00 pm*
W Hotel San Francisco 1x1 (181 Third Street)

Pfizer

Jefferies

Biren Amin

Mossrock

Thomas Malley
Hilton Union Square (333 O'Farrell Street)
Lecture

Dr. Carl June's CRISPR/Cas9 Lecture

TBD (per Petra)

1x1

ViroMed Co.

Sheila Yi

BAML

Sara Blum
Carlton Hotel (1075 Sutter St)
1x1

Recordati

Pier Paolo Ferlenga

Lake Street

Bruce Jackson

Wednesday, January 13, 2016

06:30-07:30 am* 07:00-08:00 am* 08:00-08:30 am 08:30-09:00 am 09:00-10:00 am 10:00-11:00 am 11:00-12:00 pm 12:00-01:00 pm 01:00-01:30 pm 01:30-02:00 pm 02:00-02:30 pm 03:00-04:00 pm*
ANZU at Hotel Nikko (222 Mason St)
1x1

NeoChord

David Chung

Hillhouse Capital Group

JQ Li

Piper Jaffray

Ted Tenthoff

BMO

Svetlana Makhni

venBio

Andy Washkowitz

DAFNA Capital Management

Nathan Fischel

LoneStar Heart, Inc.

Frank Ahmann and Olav Bergheim

J.P. Morgan

Cailin McGurk

Sphera Fund

Hagai Schor

Ridgeback Capital

Matt Mezvinsky

Juventas Therapeutics, Inc.

Rahul Aras
Sir Francis Drake (450 1x1

Wells Fargo Securities

-3

January 11 - 14, 2016

Powell St), Room 530

Marisa Frackman

03:00-04:00 pm*

04:00-04:30 pm* 04:00-04:45 pm* 04:30-05:00 pm* 06:00-07:00 pm* 06:00-07:00 pm*

RS Investments

Christopher Clark

Chardan Capital

Gbola Amusa

TBD

1x1

UBS

Ross Hammerman

Great Point Partners, LLC

Brett Erkman

Ono Pharma

Toichi Takino
Four Seasons Hotel (757 Market St)
1x1

Cantor Fitzgerald

Veet Misra

Thursday, January 14, 2016

08:30-09:15 am 10:00-11:00 am
Sir Francis Drake (450 1x1 Powell St)

TxCell S.A.

Miguel Forte
Hilton Union Square (333 O’Farrell Street)
1x1

Baxalta

Karla Valentin and Stefan Krauss

-4

January 11 - 14, 2016

BACKGROUNDS FOR MEETINGS
AQUILO CAPITAL MANAGEMENT, LLC

Patrick Rivers, Buy Side Analyst 415-635-0141

Rivers is an analyst at Aquilo Capital Management, LLC. He joined the firm in June 2014. Previously, Rivers was associated with Sutro Biopharma, Exelixis and Xoma. He received a BS in Chemical Engineering at UCLA and is an MBA candidate at UC Berkeley’s Haas School of Business.

Aquilo Capital Management, LLC invests in global biotechnology stocks across all market capitalizations. The firm employs: (a) fundamental; (b) technical; and, (c) charting analysis. Aquilo Capital meets with management. The firm relies on a combination of in-house analysis and sell-side research. Aquilo Capital seeks long only approach to select stocks.

AURIGA CAPITAL MANAGEMENT, LLC

Glen Losev 646-998-6474

[email protected]

Losev is a director and a senior analyst at Auriga Capital Management, LLC. Previously, he was a senior analyst at WallachBeth Capital, LLC (August 2012 - July 2013). Prior to that, Losev was an analyst at Auriga USA, LLC (August 2011-July 2012). Before that, he was an associate at The Griswold Company, Inc. Prior to that, Losev was a research associate at CitiGroup Global Markets, Inc (October 2006-June 2008). Before that, he was an analyst at Oppenheimer & Company, Inc. (October 1999-October 2006). Prior to that, Losev was an analyst at SG Pacific Asset Management (September 1996-August 1999). Losev received a BBA in Finance from Lubin School of Business at Pace University and a BA in Sociology from New York University (NYU).

Auriga Capital Management, LLC invests in U.S. stocks across all market capitalizations in healthcare and technology sectors. The firm employs sector specific long/short strategy to pick the stocks for its portfolios.

Top 10 Holdings (USD, mm) Company

Novavax, Inc.

Value

2.16 1.50 1.40 1.36 1.22 1.22

Value Change% Port

2.16 -4.04 1.40 0.35 0.80 1.22
9.46% 6.57% 6.12% 5.96% 5.35% 5.32%
Heron Therapeutics, Inc. Aerie Pharmaceuticals, Inc. Cerulean Pharma, Inc. Stemline Therapeutics, Inc. Juno Therapeutics, Inc.

-5

January 11 - 14, 2016

Colucid Pharmaceuticals, Inc. Sunesis Pharmaceuticals, Inc. Humana, Inc.
1.08 1.02 0.96 0.89
1.08 1.02 0.96 0.46
4.71% 4.48% 4.18%

3.89%

Xoma Corp.

GRANITE INVESTMENT PARTNERS, LLC – LAST MINUTE CANCELLATION

Jeffrey “Jeff” Hoo, Portfolio Manager 310-341-7140

[email protected]

Hoo is a principal, portfolio manager and an analyst at Granite Investment Partners, LLC. He joined the firm in April 2011. Previously, Hoo was a principal, portfolio manager, and a senior analyst at Transamerica Investment Management, LLC (August 2005 - March 2011). Prior to that, he was a principal and a portfolio manager at Westcap Investors, LLC (June 1997 - August 2005). Before that, Hoo was a finance manager at Sony Pictures Entertainment and an auditor at KPMG Peat Marwick. He received a BA from Duke University ('90) and an MBA from the University of California, Los Angeles (UCLA) ('98).

Granite Investment Partners, LLC (GIP) invests in U.S. growth and value stocks across all market capitalizations and sectors. The firm use fundamental analysis seeking stocks with superior business models exhibiting catalysts for positive change, which can result in rapid growth in earnings and revenue and discretionary free cash flow. Significant emphasis is placed on prudent and visionary managements with past records of success that act in the best interest of shareholders.

Top 10 Holdings (USD, mm)
Value

Company

Value

% Port

Change

0.88

Bank of the Ozarks Inc

ISHARES TR RUSSELL 2000 INDEX FUND

ABIOMED, Inc.
7.09 6.08 6.06 5.93 5.73 5.65 5.15 5.03 5.02 4.94
0.89% 0.76% 0.76% 0.74% 0.72% 0.71% 0.65% 0.63% 0.63% 0.62%
0.68 <.01

0.26

Callidus Software Inc.

Monro Muffler Brake, Inc. The Ultimate Software Group, Inc. Tyler Technologies, Inc. Pool Corporation
0.92 -0.52 0.69 0.00
Stamps.com Inc. Clovis Oncology, Inc.
-0.41 0.41

ALPINE BIOVENTURES, LLC

David Mille, Portfolio Manager

-6

January 11 - 14, 2016

206-441-5064

[email protected]

Miller is a portfolio manager and proxy contact at Alpine BioVentures, LLC. He joined the firm in August 2013. Previously, Miller was the co-founder, president, analyst and CEO of Biotechnology Stock Research, LLC. Prior to that, he was a co-founder of entrepreneurs workshop course at University of Washington, Bothell (2001 - 2010). Before that, Miller worked for Seattle Campaign (November 2008 - August 2009). Prior to that, he was an adjunct professor at University of Washington, Bothell (2002 - 2003). Before that, Miller was the CEO at Versidata (1991 - 1998). He received a BA in Communications from Western Washington University ('90).

Alpine BioVentures, LLC invests in U.S. micro- to mid- capitalization stocks across biotechnology sector. . The firm employs a long/short strategy. Alpine BioVentures conducts internal analysis and uses bulge bracket and independent sell-side research. The firm either meets or speaks on the telephone with management as part of the investment process. Alpine BioVentures is willing to travel.

TARA IMMUNO-ONCOLOGY LLC

Deshan (Desh) Govender Before Mr. Govender founded Tara Immuno-Oncology in 2014, he served as director biotech and life sciences at Iroquois Capital Management. Earlier in his career he was director of the healthcare practice at Kingsbrook Partners. He holds degrees in molecular biology and biochemistry from Wesleyan University, as well as a master’s degree in biophysics and chemistry from the WM Keck Center for Molecular Electronics at Syracuse University.

Tara I-O is a private biopharmaceutical company formed in 2014 to advance novel immuno-oncology assets. Tara I-O has offices in New York, NY, and San Diego, CA. The company is utilizing its biotechnology drug development and business expertise to advance therapies toward registration and commercialization. Management has over 25 years of development experience with a proven track record of drug approvals.

EVOLUTION LIFE SCIENCE PARTNERS

Anton Gueth Mr. Gueth is a senior leader with nearly 30 years of experience in the healthcare industry in general management, financial management, M&A advisory services, corporate/business development, alliance development and sales and marketing. He has held management roles in Europe, the Middle East, Africa and the United States. He has proven results in income growth, large-scale deal structuring and general management. He is experienced with restructuring of sales and marketing organizations, strategic planning for geographic business units and corporate alliances, and Controlling and Treasury functions. He holds a degree in agricultural economics from Justus Liebig

-7

January 11 - 14, 2016

University Giessen, and an MPA in public affairs, finance and economics from Indiana University Bloomington.

EVOLUTION Life Science Partners is an investment bank focused on the needs of life sciences and healthcare companies. They assist companies throughout their life cycle, including capital raising, licensing/partnering, and M&A. The firm’s work covers the large pharma, biotechnology, medical device, and molecular diagnostic sectors. The firm was formed in 2014 by experienced investment bankers, formerly with firms such as Lehman Brothers, Bear Stearns, Eli Lilly, GlaxoSmithKline, Bain & Company and Burrill Securities. The Firm’s Chairman, Fred Frank, is considered to be the first life sciences specialist in investment banking. He founded the biotechnology practice at Lehman Brothers. The senior bankers at EVOLUTION have an average of 25 Years of investment banking and industry experience, executing hundreds of M&A, partnering and capital raising engagements, with an aggregate deal value in excess of $125 Billion.

SILICON VALLEY BANK

Nooman Haque Nooman Haque is the Director of Healthcare & Life Sciences with Silicon Valley Bank’s UK Branch. He leads a team dedicated to supporting early, growth-stage and established businesses in all sectors of life sciences. Nooman is responsible for developing new relationships, identifying lending opportunities and working with the global life sciences team to support companies with all aspects of their business. He is actively involved within the sector, sitting on the BIA’s Finance and Tax Committee and is a frequent participant on panel and seminars. Nooman joined Silicon Valley Bank from a venture capital firm in London and previously ran a sovereign wealth fund in Saudi Arabia largely focused on healthcare. His background includes strategic and financial advisory, debt and equity structuring and risk management. Nooman has a Bsc in psychology and Msc in economics, both from the University of London, and an MBA (finance) from Imperial College. He is a member of the British Psychological Society and the Royal Economic Society.

SYNCONA PARTNERS

Tim Funnell Tim is a Partner of Syncona Partners LLP. Previously, he was a Consultant with the Boston Consulting Group where he focused on Healthcare projects, working with Pharma clients and a Global Health organisation. Tim holds a DPhil in Pharmacology from Oxford University and a MA in Natural Sciences from Cambridge University.

Syncona is an evergreen healthcare investment company that identifies and takes an active role in developing technologies to deliver transformative healthcare products. The Company was founded in October 2012 by the Wellcome Trust and all profits from the Syncona Group’s activities will be

-8

January 11 - 14, 2016

recycled to support the charitable mission of the Trust. The Company focuses on technologies with the potential to significantly impact patients and the delivery of healthcare in the future and its investments to date include companies focused on gene therapy, cell therapy and patient stratification technologies.

COWEN & CO

Chris Swindle

[email protected]

Mr. Swindle is a Managing Director in the Health Care Investment Banking Group focusing on Biotechnology and Specialty Pharmaceuticals. Mr. Swindle joined Cowen from Wedbush Pacific Growth Life Sciences where he was Managing Director and Head of Health Care Investment Banking. Previously, he was a Managing Director at Pacific Growth Equities focused exclusively on emerging and specialty pharmaceuticals banking efforts. Prior to that role, Mr. Swindle was at Jefferies & Company, Inc. and Leucadia National Corporation. Mr. Swindle holds a B.A. from the University of California, Berkeley.

Cowen Group, Inc. is a leading diversified financial services firm providing alternative investment management, investment banking, research, and sales and trading services through its business units, Ramius and Cowen and Company. Its alternative investment management products include hedge funds, fund of funds, real estate funds, healthcare royalty funds, cash management and commodity trading funds, offered primarily under the Ramius name. Cowen and Company offers industry focused investment banking for growth-oriented companies, domain knowledge-driven research and a sales and trading platform for institutional investors. Founded in 1918, the firm is headquartered in New York and has offices located in major financial centers around the world.

JEFFERIES, LLC.

Biren Amin, Analyst 212-284-8162

[email protected]

Amin is a senior research analyst at Jefferies, LLC. He joined the firm in June 2011. Previously, Amin was an analyst at WJB Capital Group (February 2010-June 2011). Prior to that, he was into biotechnology equity research at FTN Equity Capital (July 2009-February 2010). Before that, Amin was a principal at T-Rx Advisers, LLC (March 2009-July 2009). Prior to that, he was a senior vice president and biotechnology analyst at Stanford Group (November 2005-February 2009). Before that, Amin was an associate analyst at Prudential Equity Group (2004-2005). Prior to that, he was a senior manager, competitive intelligence at Aventis Pharmaceuticals (January 1999-January 2004). Amin received a BS in Pharmacy from the University of the Sciences in Philadelphia, an MS in Pharmacy from Long Island University, and an MBA from the Stern School of Business at New York University (NYU).

-9

January 11 - 14, 2016

Stocks Covered AAVL, ACRX, ADXS, ALKS, AMPE, ANTH, AQXP, BLCM, CLDX, CLLS, DYAX, EXEL, FWP, GLYC, GTXI, HRTX, IMDZ, KITE, LBIO, MDCO, MDVN, MRTX, NKTR, NLNK, ONTY, REGN, STML, TRVN, VSTM, XENE, XOMA

MOSSROCK CAPITAL, LLC

Thomas “Tom” Malley, CFA 303-808-4745

[email protected]

Malley is a president and portfolio manager at Mossrock Capital LLC. He joined the firm in 2007. Malley is also on the board of directors at Project C.U.R.E., Puma Biotechnology, Synageva BioPharma Corp, St. Anthony Health Foundation, and he is also on the board of advisors at Coachman Energy. Previously, Malley was on the board of directors at Craig Hospital (March 2007 - March 2013). Prior to that, he was on the bord of advisors at Caddis Capital (2008 2012). Before that, Malley was on the board of directors at CHI Colorado Foundation (2006 October 2011). Prior to that, he was a member of Keiretsu Forum Denver/Rockies (2007 December 2009). Before that, Malley was on the board of directors at Cougar Biotechnology (2007 2009). Prior to that, he was on the board of directors at St. Anthony's Medical Center (2004 2009). Before that, Malley was a portfolio manager at Janus Capital Group (April 1991 May 2007). He received a degree in Biology from Stanford university (’91).

Mossrock Capital, LLC invests in U.S. growth stocks across all market capitalizations and sectors.

BANK OF AMERICA SECURITIES-MERRILL LYNCH

Sara Blum 646-855-5000

[email protected]

Blum is a equity research analyst at Bank of America Securities-Merrill Lynch (U.S.) (Research). Before that, she was a treasury analyst at Bank of America Merrill Lynch. Prior to that, Blum was a Intern at Bloomberg Tradebook She attended Northwestern University.